人工智能在OCT中表征玻璃膜疣和高反射灶作为年龄相关性黄斑变性进展生物标志物
该队列研究基于HARBOR试验中518只早期或中期AMD对侧眼,利用人工智能在OCT上自动分割玻璃膜疣和高反射灶(HRF),发现两者具有不同的地形分布模式,且其厚度在进展为黄斑新生血管(MNV)、地图样萎缩(MA)或未进展眼之间存在差异,提示可作为预测疾病进展的影像生物标志物。
要点
- 玻璃膜疣和HRF在AMD进展中呈现不同的地形分布模式。
- 进展为MNV的眼中心凹玻璃膜疣厚度高于进展为MA或未进展眼。
- HRF厚度在0.5mm偏心距处进展为MA的眼最高。
核心结论
- 玻璃膜疣和HRF是AMD疾病进展的影像生物标志物,其地形模式在进展为MNV、MA或未进展眼之间不同。
- 自动定位和精确量化这些标志物可能有助于开发可靠的疾病进展预测方法。
研究设计与样本
- 队列研究,纳入HARBOR试验中早期或中期AMD对侧眼的OCT容积数据,共518只眼,每月成像持续2年。
- 使用经过验证的人工智能算法在三维中自动分割玻璃膜疣和HRF体积,并将所有扫描映射到联合参考框架以获取地形对应。
主要发现
- 24个月随访期间,135眼(26%)进展为MNV,50眼(10%)进展为MA,333眼(64%)未进展为晚期AMD。
- 中心凹平均玻璃膜疣厚度:进展为MNV眼29.6 μm(95% CI, 20.2-39.0 μm),进展为MA眼17.2 μm(95% CI, 9.8-24.6 μm),未进展眼17.1 μm(95% CI, 12.5-21.7 μm)。
- 0.5-mm偏心距平均玻璃膜疣厚度:进展为MNV眼25.8 μm(95% CI, 19.1-32.5 μm),进展为MA眼21.7 μm(95% CI, 14.6-28.8 μm),未进展眼14.4 μm(95% CI, 11.2-17.6 μm)。
- 中心凹平均HRF厚度:进展为MNV眼0.072 μm(95% CI, 0-0.152 μm),进展为MA眼0.059 μm(95% CI, 0-0.126 μm),未进展眼0.044 μm(95% CI, 0.007-0.081 μm)。
- 0.5-mm偏心距平均HRF厚度:进展为MA眼0.227 μm(95% CI, 0.104-0.349 μm),进展为MNV眼0.161 μm(95% CI, 0.101-0.221 μm),未进展眼0.085 μm(95% CI, 0.058-0.112 μm)。
临床怎么用
- 利用AI自动分割OCT上的玻璃膜疣和HRF,可量化其地形分布,辅助识别AMD进展高风险眼。
- 对于早期或中期AMD对侧眼,关注中心凹及0.5mm偏心距的玻璃膜疣和HRF厚度变化,可能有助于预测MNV或MA的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The morphologic changes and their pathognomonic distribution in progressing age-related macular degeneration (AMD) are not well understood. OBJECTIVES: To characterize the pathognomonic distribution and time course of morphologic patterns in AMD and to quantify changes distinctive for progression to macular neovascularization (MNV) and macular atrophy (MA). DESIGN, SETTING, AND PARTICIPANTS: This cohort study included optical coherence tomography (OCT) volumes from study participants with early or intermediate AMD in the fellow eye in the HARBOR (A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration) trial. Patients underwent imaging monthly for 2 years (July 1, 2009, to August 31, 2012) following a standardized protocol. Data analysis was performed from June 1, 2018, to January 21, 2020. MAIN OUTCOMES AND MEASURES: To obtain topographic correspondence between patients and over time, all scans were mapped into a joint reference frame. The time of progression to MNV and MA was established, and drusen volumes and hyperreflective foci (HRF) volumes were automatically segmented in 3 dimensions using validated artificial intelligence algorithms. Topographically resolved population means of these markers were constructed by averaging quantified drusen and HRF maps in the patient subgroups. RESULTS: Of 1097 patients enrolled in HARBOR, 518 (mean [SD] age, 78.1 [8.2] years; 309 [59.7%] female) had early or intermediate AMD in the fellow eye at baseline. During the 24-month follow-up period, 135 (26%) eyes developed MNV, 50 eyes (10%) developed MA, and 333 (64%) eyes did not progress to advanced AMD. Drusen and HRF had distinct topographic patterns. Mean drusen thickness at the fovea was 29.6 μm (95% CI, 20.2-39.0 μm) for eyes progressing to MNV, 17.2 μm (95% CI, 9.8-24.6 μm) for eyes progressing to MA, and 17.1 μm (95% CI, 12.5-21.7 μm) for eyes without disease progression. At 0.5-mm eccentricity, mean drusen thickness was 25.8 μm (95% CI, 19.1-32.5 μm) for eyes progressing to MNV, 21.7 μm (95% CI, 14.6-28.8 μm) for eyes progressing to MA, and 14.4 μm (95% CI, 11.2-17.6 μm) for eyes without disease progression. The mean HRF thickness at the foveal center was 0.072 μm (95% CI, 0-0.152 μm) for eyes progressing to MNV, 0.059 μm (95% CI, 0-0.126 μm) for eyes progressing to MA, and 0.044 μm (95% CI, 0.007-0.081) for eyes without disease progression. At 0.5-mm eccentricity, the largest mean HRF thickness was seen in eyes progressing to MA (0.227 μm; 95% CI, 0.104-0.349 μm) followed by eyes progressing to MNV (0.161 μm; 95% CI, 0.101-0.221 μm) and eyes without disease progression (0.085 μm; 95% CI, 0.058-0.112 μm). CONCLUSIONS AND RELEVANCE: In this study, drusen and HRF represented imaging biomarkers of disease progression in AMD, demonstrating distinct topographic patterns over time that differed between eyes progressing to MNV, eyes progressing to MA, or eyes without disease progression. Automated localization and precise quantification of these factors may help to develop reliable methods of predicting future disease progression.
引用
- Waldstein SM, Vogl WD, Bogunovic H, et al. Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography. JAMA Ophthalmol. 2020. PMID: 32379287. doi:10.1001/jamaophthalmol.2020.1376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。